New Delhi: The Association of Biotechnology Led Enterprise (ABLE), a pan-India forum that represents the Indian biotechnology sector and the Forum for Innovative Regenerative Medicine (FIRM), an industry organization with a mission to accelerate research and commercialization of regenerative medicine in Japan have entered into a collaborative agreement to work together to advance regenerative medicine and cell and gene therapies within India, Japan and internationally.

The collaborative programs between ABLE and FIRM will focus on advancing the individual and common missions by sharing information including technology, policy, laws etc partnerships and opportunities such as co-sponsoring meetings and other cooperation based on common concern. The partnership is a unique platform to advance and promote commercialization of life-saving products in regenerative medicine in both the countries.

The partnership is a step forward to enhance the learning and training, leading to enhancement of the cell and gene therapies which could help to address major unmet medical needs in India.

The Memorandum of Understanding was signed by Mr Manohar, CEO, Stempeutics Research and Head – Committee for Regenerative Medicine Group, Association of Biotech Led Enterprises (ABLE) and Mr Yuzo Toda, Senior Executive Vice President, CTO, Director, FUJIFILM Corporation & Chairman, Forum for Innovative Regenerative Medicine (FIRM) in the presence of Dr Jagdish Prasad – Director General of Health Services (DGHS), Government of India and Dr V G Somani– Additional Drug Controller General of India (DCGI), Government of India and other eminent dignitaries.

On the occasion of this collaboration, Mr Manohar, CEO, Stempeutics Research and Head – Committee for Regenerative Medicine Group, Association of Biotech Led Enterprises (ABLE) said, “We are proud to be a partner of the prestigious Forum for Innovative Regenerative Medicine (FIRM) in this revolutionary research and industry collaborations. The partnership is a step forward to enhance the learning and training on cell and gene treatment leading to enhancement of the cell and gene therapies which help to address major unmet medical needs in India. We look forward to working with FIRM and contribute towards controlling and curing major human illness.”

“Regenerative medicine and cell & gene therapies are the most noteworthy developing innovation according to medical, biotechnology and pharmaceuticals. Our association with ABLE is an opportunity to work towards the advancement of the field and tap on the potential to transform human healthcare. Through the partnership, we can share learnings and insights to contribute towards curing major human illness.” said, Mr Takuya Yokokawa- Healthcare Business Development, Fujifilm Corporation & Chair, Steering Committee, Forum for Innovative Regenerative Medicine (FIRM).